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1. Introduction
Options for renal replacement therapy (RRT) for patients with end-stage kidney disease
(ESKD) include haemodialysis, peritoneal dialysis and renal transplantation. Although renal
transplantation offers the best outcomes in terms of quality and quantity of life, most patients
with ESKD will be treated with dialysis, either because they are ineligible for transplantation
due to their burden of comorbid medical conditions, or because they commonly have to wait
several years on dialysis before they are able to receive a kidney transplant. Survival of patients
on dialysis remains poor, with reported annual mortality rates ranging from 12.7% in Australia
and 14.6% for New Zealand [1] to 17.9% in Europe [2] to 25% in the United States of America
[3]. Alternative ways of delivering dialysis that will materially improve patient outcomes are
therefore required.
Emerging data suggest that haemodiafiltration (HDF), a form of haemodialysis that combines
both diffusive and convective solute removal, may offer clinical benefits when compared to
standard high-flux haemodialysis (HD). Despite these findings, the global uptake of haemo‐
diafiltration is variable and generally low, ranging from minimal use in the United States, 3.1%
in the United Kingdom to 6% in Australia and 28.8% in Belgium [2]. This chapter will provide
an overview of the principles and technical aspects of haemodiafiltration, as well as review
the clinical evidence comparing HDF outcomes with those of HD.
2. Diffusive versus convective therapy
Physical removal of solutes across a dialysis membrane occurs via diffusion (passive move‐
ment down a concentration gradient) and/or convection (obligatory “dragging” of solutes by
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fluid removal across the dialysis membrane, i.e. solvent drag) [4]. Some solutes, especially
proteins, may also be removed to a limited extent by adsorption to the dialysis membrane.
In conventional low-flux haemodialysis, solute clearance predominantly occurs via diffusion
across the dialysis membrane in a counter-current set up whereby blood flows in one direction
and the dialysate flows in the other (Figure 1). Solutes move across the semi-permeable dialysis
membrane down a concentration gradient. The factors that lead to a higher rate of diffusive
exchange are 1) larger concentration gradient; 2) larger membrane pore size; 3) smaller solute
molecular size; 4) larger exchange surface area; 5) higher blood flow rate; and, 6) higher
dialysate flow rate. Diffusion represents the main mechanism for removal of low molecular
weight molecules (<500 Daltons), such as urea (60 Da) and creatinine (113 Da), but is relatively
inefficient at removing middle molecules (500 – 60,000 Daltons) [5], such as β2-microglobulin
(11,500 Da), and does not appreciably remove large molecules (>60,000 Da), such as albumin
(66,500 Da). This limitation can be overcome to a certain extent by the use of high-flux dialysis
membranes with a larger pore size. High-flux dialysers permit increased blood water transfer
across the membrane at the proximal end of the dialyser, compensated by the phenomenon of
backfiltration, in which dialysate flows across the membrane at the distal end of the dialyser
under a hydrostatic pressure gradient. Concentration of plasma proteins in the blood com‐
partment will also exert osmotic pull, further contributing to backfiltration [6]. This process
results in “internal” convection of up to 5-10L per dialysis treatment, and improves clearance
of middle molecules compared to low-flux dialysis.
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Figure 1. Conventional haemodialysis. A solute, shown dissolved in blood, moves across the semi-permeable dialysis
membrane by diffusion, into the dialysate, with blood and dialysate flowing in opposite directions (countercurrent).
The rate of diffusion is dependent on the initial concentration in the blood, the blood flow rate, the permeability of the
membrane for the solute, and the dialysate flow rate. Removal of water (ultrafiltration) is determined largely but the
pressure across the membrane.
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In contrast to haemodialysis, haemofiltration clears solutes primarily via convection, allowing
water and solutes up to 20 kDa to cross the membrane and achieving more efficient removal
of middle and large molecular weight solutes (Figure 2). The factors that lead to a higher rate
of convective removal of solute are 1) volume of ultrafiltration, 2) a higher sieving coefficient
(solute concentration in the ultrafiltrate divided by plasma concentration) and 3) a higher
transmembrane pressure (which leads to a higher ultrafiltration rate) [7]. Given that haemo‐
filtration is dependent upon large volume ultrafiltration, replacement fluid needs to be infused
back into the patient to prevent excessive fluid removal. However, although haemofiltration
provides efficient clearance of middle and large molecular weight molecules, it is less efficient
at removing small molecular weight solutes than conventional haemodialysis.
   
blood 
semi‐permeable 
dialysis membrane 
filtrate 
solute 
water 
movement
Figure 2. Haemofiltration (convection). Movement of water across the more water-permeable membrane ‘drags’ solute
across, and leads to production of a filtrate which contains the solute. Solute removal is largely dependent on the ultra‐
filtration rate, but is limited by haemoconcentration and so ‘pure’ haemofiltration is not practical without replacement
of fluid.
The distinct and separate advantages of haemofiltration (efficient middle and large molecule
clearance) and haemodialysis (efficient small solute clearance) are combined by the technique
of HDF, which provides both diffusive and convective clearances (Figure 3). This theoretically
offers better overall clearance of small, middle and large molecular weight substances. HDF
can produce convective volumes of greater than 20L per session, and this can be achieved by
several different means:
1. “Internal” HDF: Achieved through the process of backfiltration in high flux haemodial‐
ysis. As mentioned above, this results in smaller convective volumes compared to
dedicated HDF modality.
2. Classical HDF: Characterised by the use of an external substitution fluid in the form of
sterile solution stored in plastic bags. Logistic and cost issues limit the use of this modality.
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3. Online HDF: A form of HDF whereby substitution fluid is produced by the dialysis
machine, creating ultrapure dialysate that is sterile, non-pyrogenic, continuous and
unlimited while the machine is in operation [4].
As discussed later in the chapter, convective volume, and therefore enhanced removal of larger
uraemic toxins, has emerged as an important parameter in outcomes relating to convective
therapies. Convective dose is defined as the total ultrafiltered volume, which equates to the
sum of volume gained/lost and substitution fluid given [7]. Convective dose has been proposed
as the key quantifier of online-HDF by the European Dialysis (EUDIAL) group [8].
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Figure 3. Haemodiafiltration (HDF). HDF combines dialysis and filtration across a semi-permeable membrane but uses
much larger volumes of dialysate. Extra ultrapure water can be added either pre-dilution or post-dilution to replace
the filtrate. Small solutes are removed largely by diffusion whereas larger solutes (middle molecules) are removed by
convection. Water removal (ultrafiltration) is regulated by varying the volume of replacement fluid.
3. Important considerations for haemodiafiltration
3.1. Membrane
Haemodialysis and haemodiafiltration utilise filter membranes composed of cellulose,
substituted cellulose or synthetic material. The ideal membrane will provide both solute
removal capability as well as biocompatibility [9]. Contact of blood with dialysis membranes
elicits inflammatory response, including activation of complement system, polymorphonu‐
clear cells and mononuclear cells [10]. A biocompatible membrane is one that elicits the least
amount of inflammatory response in patients exposed to it [11]. Membranes can be described
in terms of their efficiency (rate of removal of small solutes) and flux (rate of removal of middle
molecules).
High-flux membranes can remove molecules as large as 20kDa, which is better than a tradi‐
tional low-flux membrane, but still inferior to glomeruli, which can clear molecules up to
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65kDa [12]. ‘Super high-flux’ or ‘high cut-off’ membranes have been developed to remove
larger molecules of up to 50-60kDa, in an attempt to remove larger uraemic toxins and
inflammatory mediators [12, 13]. Early data using these membranes have indicated enhanced
clearance of free light chains and myoglobin, in patients with myeloma and rhabdomyolysis
respectively, although larger clinical trials are required to demonstrate their impact on
important clinical outcomes. Loss of important serum proteins such as albumin is significant,
and represents a potential disadvantage of using ‘high cut-off’ membranes, because of the risk
of protein malnutrition [12].
3.2. Ultrapure dialysate
Convective therapies result in infusion of substantial quantities of dialysate and substitution
fluid, and a major challenge in HDF is the generation of ultrapure dialysate that is sterile and
non-pyrogenic. This is because dialysate contaminants can enter the blood via convection or
by direct infusion as substitution fluid [14]. The European Best Practice Guidelines (ERPG),
American National Standards Institute / Association for Advancement of Medical Instrumen‐
tation (ANSI/AAMI) and International Organization for Standardisation (ISO) all mandate
that ultrapure fluid contains no more bacteria than 0.1 colony forming units (CFU)/mL, and
endotoxins no more than 0.03 endotoxin unit (EU)/mL [14]. Previous studies indicate that
ultrapure dialysate improves inflammation-related parameters such as C-reactive protein [14],
albumin and haemoglobin [14-17], although endpoints such as mortality and cardiovascular
events have not been adequately demonstrated in high quality trials to date.
3.3. Site of fluid replacement
In HDF, ultrafiltration for convective solute clearance necessitates that replacement fluid is
administered to maintain appropriate fluid balance. The site at which the replacement fluid is
infused has an important impact on several dialysis variables.
In post-dilution mode, replacement fluid is added to the venous side of the circuit, distal to
the filter. The convective clearance is the same as the volume of filtrate. This is the most efficient
form of HDF, with respect to solute clearance, however this modality is complicated by the
effects of haemoconcentration. At high ultrafiltration rates the haematocrit rises within the
dialyser, increasing the risk of the filter clotting as well as membrane pore occlusion caused
by adherence of plasma proteins [8]. Haemoconcentration is proportional to the filtration
fraction, typically defined as the ratio of ultrafiltration rate to blood flow rate, which is usually
limited to <25% in post-dilution HDF, and necessitates a high blood flow rate [6].
In pre-dilution mode, replacement fluid is given to the arterial side of the circuit, diluting blood
before it is filtered. This mitigates the effect of ultrafiltration on haemoconcentration, but at
the cost of reducing the efficiency of both diffusive and convective solute clearance. As a result,
to achieve equivalent clearances, the ultrafiltration rate is typically set two-fold higher when
performing pre-dilution HDF compared to post-dilution HDF. While many centres use post-
dilution HDF, dialysis centres in Japan have more experience employing pre-dilution HDF [18,
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19]. From their experience, pre-dilution has comparable effects on removal of uraemic toxins,
reduces shear stress and results in stable blood pressures during treatment [18].
Recently, mid-dilution HDF has been made possible with the development of specialised
dialysis circuits that permit infusion of replacement fluid between an initial post-dilution and
subsequent pre-dilution stage. The advantage of this design is the ability to allow higher
reinfusion rates, and early studies show better clearance of urea, β2-microglobulin and
phosphate compared with high-flux HD [20, 21].
Finally, mixed dilution combining pre-and post-dilution has been developed with the aim of
providing the most safe and efficient clearance of solutes. A small study of ten patients
suggested that mixed dilution may provide superior clearances compared to mid-dilution,
citing high transmembrane pressures in the mid-dilution dialyser potentially compromising
membrane permeability and therefore infusion rate [22]. While different modes of fluid
replacement in HDF have demonstrated advantages and disadvantages in small pilot studies,
more data from larger studies are required to convincingly demonstrate the relative efficacy
and safety of each method. For now, regional availability and experience tend to dictate the
method utilised.
3.4. Cost effectiveness
One important consideration when deciding whether to adopt HDF is that of cost and cost-
effectiveness. One French centre estimated that for each session, additional consumables (-
€2.55 to+€3.35), microbiological analysis (€1.10) and water consumption (€0.15 to €0.23, based
on 50.8 to 74.8 L), resulted in a cost of €-1.29 to €+4.58 per session for HDF over conventional
HD [23]. Another cost analysis conducted in the United Kingdom over a 12 month period
comparing HDF and high-flux HD found variable consumables costs (-£0.78 to+£1.16, de‐
pending on type of line used), similar erythropoiesis stimulating usage and less phosphate
binder use (£3.8 and £5.0 weekly) in the HDF group [24].
A cost analysis of HDF versus haemodialysis was performed based on data from the CON‐
TRAST study (mentioned later in the chapter) comparing low-flux HD and HDF. It was found
that the annual costs for HDF and HD were €88,722 ± 19,272 and €86,086 ± 15,945, respectively,
in 2009 in Europe [25]. However, when cost-utility analysis was applied to assess difference
in quality of life, the incremental cost per quality-adjusted year (QALY) of HDF over HD was
€287,769. Based on this analysis, the authors concluded that HDF was not cost effective, as
concurred by McBrien, et al [26].
3.5. Potential role in home haemodialysis
To date, little data has been published regarding HDF utlisation in the home setting. This is
not surprising, given that it is yet to be established as the predominant method of haemodial‐
ysis. If applied in the home setting, an extra filter used to produce ultrapure dialysate may
provide benefits relating to inflammatory parameters, as mentioned above.
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4. Clinical benefits of HDF compared with HD
4.1. Mortality
The first large randomised trial performed to compare different doses and flux of dialyser was
published in 2002. The Effect of Dialysis Dose and Membrane Flux in Maintenance Hemo‐
dialysis (HEMO) study [27] was a two-by-two factorial design randomised controlled trial
which enrolled 1846 patients between 1995 and 2000, and assigned them to receive standard
dose (Kt/V urea of 1.05) or high dose (Kt/V urea of 1.45) dialysis, and to a low-flux or high-flux
dialyser. Flux was estimated based on β2-microglobulin clearance, with the low-flux group
achieving 3±7mL/min and the high-flux group achieving 34±11mL/min. The primary outcome
measured was death from any cause, with mean follow up of 2.84 years. The study found 0.166
deaths per patient-year, and that the rate of mortality did not vary significantly across the
groups [27].
However, potential survival benefit from convective therapy was suggested by subsequent
clinical data, such as the Dialysis Outcomes and Practice Pattern Study (DOPPS) – Mortality
risk for patients receiving haemodiafiltration versus haemodialysis: European results from the
DOPPS [28]. In this prospective cohort study involving 2165 patients recruited between 1998
and 2001, patients were stratified into four groups: low-or high-flux HD, low-or high-efficiency
HDF. The usage of HDF varied greatly between countries, with 1.8% in Spain and up to 20.1%
in Italy [28]. Adjusted mortality rate showed high-efficiency HDF patients had a 35% lower
mortality risk than those receiving low-flux HD (p=0.01) [28], suggesting that high convective
clearance lowers risk of death, independent of dialysis dose. However, this needs to be
considered in the context of the observational nature of the study and possible selection bias
with residual confounding.
In a Cochrane review in 2009, published evidence on HDF, HF and HD were compared,
including 20 randomised trials. There was no significant difference in mortality or hospitali‐
sations [29] between the 3 treatment modalities. However, given the relatively small number
of patients in the studies and their heterogeneous nature, the conclusion of this review
suggested that larger studies would be needed to prove the benefit of convective therapies.
Recently, three large, randomised controlled trials have compared haemodiafiltration with
haemodialysis. While their designs were slightly different, they all measured important
patient-level outcomes such as mortality, cardiovascular events, and hospitalisations, amongst
others. These three trials were, respectively, the Convective Transport Study (CONTRAST)
[30], Comparison of Post-dilution Online Haemodiafiltration and Haemodialysis (Turkish OL-
HDF study) [31] and Online Haemodiafiltration Survival Study (ESHOL: Estudio de Supervi‐
vencia de Haemodiafiltracion) [32]. These three trials will be described in further detail.
In the CONTRAST study, 714 patients across the Netherlands, Canada and Norway, recruited
between 2004 and 2009, were enrolled and randomised to post-dilution online HDF (n=358)
or low-flux HD (n=356) [30]. One of the remarkable feats of this study was the achievement of
100% follow up. The mean follow up was 3.04 years. No significant difference was observed
between the treatment groups with respect to the primary outcome measure of all-cause
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mortality (HR 0.95, 95% CI 0.75-1.20), even after adjustment for potential confounders.
However, a subsequent post hoc analysis, indicated that patients who achieved a higher
convective volume (>21.95 L per session), experienced a 38% risk reduction for mortality
compared to the low-flux HD group (p=0.012). A potential limitation is that the pre-defined
target convection of 6 L per hour (based on modelling calculations) was not reached: the mean
convection volume was 20.7 L, and one third of patients received 18 L or less, mainly caused
by inadequate vascular access [33].
In the Turkish OL-HDF study, 782 ESKD patients recruited between 2007 and 2008 were
randomised to receive high-flux HD (n=391) or post-dilution online HDF (n=391) over a mean
follow-up period of 22.7 months [31]. The primary outcome was a composite of all-cause
mortality and non-fatal cardiovascular events. The investigators did not find a significant
difference in event free survival (HD group 74.8% versus OL-HDF 77.6%, p=0.28). However,
on post hoc analysis, it was again demonstrated that OL-HDF patients who received higher
convective volumes (> 17.4 L per session) experienced a 46% lower risk of mortality (p=0.02)
after adjustment for other potential risk factors [31]. Patients recruited in this study had spent
considerably longer time on dialysis (average 57.9 months), and therefore mortality rate was
likely affected by survival selection bias. The average age of patients selected was also far
younger at 56.5 years.
The ESHOL study was an open-label, randomised controlled trial conducted in Catalonia,
Spain [32]. 906 patients recruited between 2007 and 2008 who were already on haemodialysis
were randomised to receive high-flux haemodialysis (n=450) or post-dilution online HDF
(n=456). Unlike CONTRAST and the Turkish OL-HDF study, the ESHOL study specifically
targeted high convective volumes in the HDF group. The median follow up was 2.08 years
and the primary outcome measured was all-cause mortality. At 3 years, the detected mortality
rate was 27.1% in the HD group compared to 18.6% in OL-HDF group (30% risk reduction,
hazard ratio 0.53-0.92, p=0.01), in contrast with the two above studies. They also detected a
lower risk of stroke (HR 0.39, p=0.03) and lower rate of hospitalisations (HR 0.78, p=0.001)
It is interesting that the three trials, conducted at similar times, produced different outcome
results for all-cause mortality. Based on the post-hoc analyses of CONTRAST and the Turkish
OL-HDF suggesting a mortality benefit in patients achieving higher convective volumes, a
possible explanation for the difference is the higher convective volume achieved in the ESHOL
trial (mean of 22.9 – 23.9 L per session, compared with 20.7L per session in CONTRAST and
17.2L per session in the Turkish OL-HDF). Furthermore, there was a difference in time already
on dialysis at the point of randomisation, which may have contributed to lead-time bias.
Different practices in various regions may also have led to centre-effect bias.
A meta-analysis undertaken in early 2014 (Wang A, et al) analysed 16 randomised controlled
trials published thus far comparing HD and HF/HDF in terms of cardiovascular outcomes and
mortality [34]. Of these, 11 included HDF, 4 incorporated HF, and one included either
modality. The three recently published randomised trials contribute to the majority of the data
analysis, due to their large patient numbers. The authors did not find significant reduction
associated with convective therapies in terms of cardiovascular events (RR 0.85, 95% CI 0.66 –
1.10) or all-cause mortality (RR 0.83, 95% CI 0.65 – 1.05). There was reduction in symptomatic
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hypotension (RR 0.49, 95% CI 0.30 – 0.81) and improved β2-microglobulin levels (-5.95mg/L,
95% CI-10.27 to – 1.64mg/L) [34].
CONTRAST [30] Turkish OL-HDF [31] ESHOL [32]
Total patient number 714 782 906
Control group Low-flux HD (n = 356) High-flux HD (n = 391) High-flux HD (n = 450)
HDF group Post-dilution HDF (n = 358) Post-dilution HDF (n = 391) Post-dilution HDF (n = 456)
Average patient age 64.1 years 56.5 ± 13.9 years 65.4 ± 14.4 years
Prior time on dialysis 34.8 ± 33.6 months 57.9 ± 44.6 months 28.0 (12 – 59) months
Mean follow up 3.04 yrs, range 0.4-6.6 22.7 ± 10.9 months 1.91 ± 1.10 years
Primary outcomes measured All-cause mortality All-cause mortality
Non-fatal CV events
All-cause mortality
Secondary outcomes
measured
Fatal & non-fatal CV events CV mortality
Intradialytic complications
Hospitalisation rate
Laboratory parameters
CV mortality
Hospitalisation
Treatment tolerability
Laboratory parameters
Ultrapure dialysate used for
both groups
Yes Not specified Yes
Convective volume on HDF 20.7 L / session 17.2 ± 1.3 L / session 22.9 – 23.9 L / session
β2 microglobulin reduction HDF: 4.3 mg/L
HD: -3.1 mg/L (p < 0.001)
HDF: 0.67 ± 9.57 mg/L
HD: -0.59 ± 9.02 mg/L
Not specified
Primary outcome result Incidence HDF 121 vs HD 127
per 1000 person-yrs (95% CI
0.75-1.20)
*Post hoc: HDF with convective
volume > 21.95L/ session 38%
RR for mortality, p = 0.012
Event free survival HDF
77.6%, HD 74.8%, p = 0.28
*Post hoc: HDF with convective
volume > 17.4L/ session 46%
RR for mortality, p = 0.02
3 year mortality rate HDF
18.6% vs HD 27.1% ( p = 0.01)
*HD=haemodialysis, *HDF=haemodiafiltration, *CV=cardiovascular, *CI=confidence interval
Table 1. Comparison of recent randomised controlled trials
Another review performed by Mostovoya, et al. focused on six published randomised
controlled trials only, namely The Italian Cooperative Dialysis Study Group [35], Hemofiltra‐
tion and haemodiafiltration reduce intradialytic hypotension in ESRF [36], Efficacy of haemo‐
diafiltration [37], alongside CONTRAST, Turkish OL-HDF and ESHOL. In this meta-analysis,
HDF was found to have a decreased risk of mortality (RR 0.84, 95% CI 0.73-0.96) and cardio‐
vascular death (RR 0.73, 95% 0.57-0.92) [38]. Data interpretation needs to be taken with caution
given the heterogeneous mix of pre-, mid-and post-dilution modes used, as well as different
convective volumes achieved.
While these two systematic reviews drew different conclusions based on different trials
included in their analyses, there did appear to be a signal suggesting possibly reduced
mortality and cardiovascular events when higher convective volumes were achieved. Indeed,
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in the CONTRAST study [30], convective volumes exceeding 21.95L were associated with a
38% risk reduction. Similarly, in the Turkish OL-HDF trial [31], convective volumes exceeding
17.4 L per session were associated with a 46% risk reduction in mortality. The ESHOL trial
showed a difference in mortality, but it achieved higher convective volumes (22.9 – 23.9 L per
session) [32] than the CONTRAST and Turkish OL-HDF trials.
4.2. Intradialytic hypotension
In meta-analyses, symptomatic hypotension was reduced by HDF compared to HD, with RR
of 0.49 [34]. The ESHOL trial reported significant difference in occurrence, with 769.2 episodes
per 100 patient-years in the HDF group compared with 937.7 episodes (P<0.001) [32].
4.3. Blood pressure and fluid control
Post-dialysis systolic blood pressure was not significantly affected by treatment modality [34].
The CONTRAST study reported insignificantly different pre-dialysis systolic blood pressure
of 146 mmHg for HDF compared to 145 with low-flux HD, and intradialytic weight gain of 1.9
vs 1.85kg [30]. There was also no significant difference in systolic blood pressure in the Turkish
study, however a difference in interdialytic weight gain was detected: 3.19% of body mass in
the HD group, 3.87% in the low-efficiency HDF group and 3.29% in the high-efficiency group
[31]. The ESHOL trial reported no difference in blood pressure levels [32].
4.4. Left ventricular mass
Higher left ventricular mass (LVM) has been associated with cardiovascular and overall
mortality in patients on dialysis [39, 40]. A subset of 327 patients from the CONTRAST study
was assessed in terms of their LVM at baseline with echocardiography [41]. These patients
were stratified into tertiles, and those in the highest tertile (LVM > 260grams) had the highest
risk of mortality, cardiovascular death and sudden death. So far one small trial involving 22
patients utilising HDF has demonstrated improvement in left ventricular mass index (131.9 to
116.5 g/m2) at 1 year [42]. This surrogate marker will need to be more extensively studied to
convincingly demonstrate potential long term clinical effect.
4.5. Dialysis related β2-microglobulin amyloidosis
Dialysis related amyloidosis is a syndrome of pain and loss of function due to deposition of
amyloid composed of β2-microglobulin in the musculoskeletal system. While β2-microglobu‐
lin can be removed on dialysis, pre-dialysis levels often remain elevated [43]. The CONTRAST
study demonstrated lower β2-microglobulin level in the HDF group (26.4 mg/L) compared to
the HD group (35.4 mg/L), as well as a greater reduction in its level post treatment (4.3 mg/L)
[30]. On the other hand, patients in the Turkish study had very similar levels, and achieved a
much smaller reduction of 0.67 mg/L [31]. While advancements in renal replacement therapy
have allowed manipulation in β2-microglobulin levels, enhanced clearance has not yet
translated to clinical difference in dialysis related amyloidosis, particularly given the long
periods required for the syndrome to manifest.
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4.6. Inflammatory markers
Inflammation in chronic kidney disease has been associated with a range of negative outcomes,
including cardiovascular mortality [44], atherosclerosis, protein energy wasting, hypo-
responsiveness to erythropoiesis stimulating agents (ESAs), platelet dysfunction and endo‐
crine dysfunction [45]. Chronic inflammation is caused by both cytokine dysregulation in
chronic kidney disease [46], and the dialysis process itself [47]. A subset of patients from the
CONTRAST study was screened for markers of inflammation, including C-reactive protein
(CRP) and interleukin-6 (IL-6) [48]. 201 patients from the HDF arm and 204 patients from the
HD arm were selected for this study. Baseline CRP levels were 3.0 mg/L in the HD group and
4.1 mg/L in the HDF group. After 3 years, there was a significant steady rise in CRP level in
the HD group (~20% per year) whereas it remained stable in the HDF group. Similarly, IL-6
levels increased in the HD group but not for HDF patients. Both of these figures were adjusted
for confounders including age, sex and residual renal function, and still remained significant
[48]. Given that ultrapure dialysate were used for both groups, the different measurements
appear to have arisen from different modalities of dialysis.
4.7. ESA hypo-responsiveness
Another clinical outcome examined by the CONTRAST investigators was whether use of HD
or HDF resulted in a difference in resistance to erythropoiesis stimulating agents. This was
done given the proposed concept that better clearance of middle molecular weight uraemic
toxins would reduce inflammation, and therefore improve responsiveness to ESAs [49].
Starting at statistically similar haemoglobin levels (11.9 g/dL in HDF, 11.8 g/dL in HD), with
iron replete, they measured ESA index (weekly weight adjusted ESA dose divided by haema‐
tocrit) as a measure of ESA resistance. After 12 months, there was no significant difference
found [50]. This finding is in keeping with an earlier randomised controlled study involving
146 patients where allocation to low flux HD or HF/HDF did not improve haemoglobin levels
or ESA resistance [51].
4.8. Quality of life measurement
Assessment quality of life is difficult, due to the subjective nature of outcomes as well as
different  assessment  of  tools  used.  One study reported lower  physical  wellbeing  scores
while  on  HD[52],  however  meta-analyses  have  shown  inconsistent  and  insignificant
differences in quality of life, particularly when measured with Kidney Disease Quality of
Life Questionnaire [34, 53].
5. Further trials
As of September 2014, there are several proposed trials currently underway to further elucidate
potential clinical benefits of haemodiafiltration, as registered on ClinicalTrials.gov [54]:
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• Mid-dilution Hemodiafiltration International Randomised Prospective on Incident Patients
Focused on Outcome (MILESTONE) [55]
◦ Trial identifier: NCT01693354
◦ Purpose: “to determine whether mid-dilution haemodiafiltration is effective in the
reduction of the crude mortality risk in patients who have been undergoing renal
replacement treatment for less than 1 year. Patients will be randomized since the
beginning of the study in two groups: standard HF dialysis and mid-dilution HDF”
◦ Study type: interventional
◦ Estimated enrolment: 800
◦ Arms: HF dialysis vs. mid-dilution HDF
◦ Primary outcome: crude, all-cause mortality at 5 years
• Tolerance of “On Line” Hemodiafiltration and Impact on Mortality and Cardiovascular Risk
Factor in Chronic Renal Failure Patients [56]
◦ Trial identifier: NCT01327391
◦ Purpose: “to appreciate the tolerance of "on line" hemodiafiltration and its impact on
morbidity and cardiovascular risk factors in chronic renal failure patient.”
◦ Study type: interventional
◦ Estimated enrolment: 600
◦ Arms: on line hemodiafiltration vs high flux hemodialysis
◦ Primary outcome: tolerance of online HDF in terms of adverse events occurring during
dialysis sessions
• Randomised Study of High-flux Haemodialysis and Haemodiafiltration [57]
◦ Trial identifier: NCT01862679
◦ Purpose: to answer the following three main questions in regards to HDF and high-flux
HF
▪ Does HDF make patients feel better?
▪ Is blood pressure more stable on HDF in comparison with HF-HD?
▪ Are Phosphate levels and other blood parameters better controlled with HDF than HF-
HD?
◦ Study type: interventional
◦ Estimated enrolment: 100
◦ Arms: HF-HF and HDF, crossover at 8 weeks
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◦ Primary outcome: change in the average time taken to fully recover post dialysis
• The Effects of Haemodiafiltration vs Conventional Haemodialysis on Growth and Cardio‐
vascular Markers in Children – 3H (HDF, Hearts and Height) Study [58]
◦ Trial identifier: NCT02063776
◦ Purpose: to monitor growth, heart and blood vessel scans, blood markers and quality of
life in children
◦ Study type: Observational case control
◦ Estimated enrolment: 150
◦ Arms: children on HDF, children on conventional HD
◦ Primary outcome: change in carotid intimate thickness standard deviation score, change
in height standard deviation score
6. Conclusion
Haemodiafiltration, utilising convection via high-flux dialysers and ultrapure dialysate, has
been shown to exhibit certain advantages over conventional haemodialysis, such as a reduction
of intradialytic hypotension, reduction of left ventricular mass and lower β2-microglobulin
levels. However, when it comes to important patient-level outcomes such as mortality and
cardiovascular events, HDF has not been shown conclusively to be of benefit, although studies
to date have been limited by inadequate statistical power and suboptimal methodological
quality. It may be that a minimum amount of convective volume needs to be achieved to
demonstrate mortality benefits, and that this volume may be in the order between 17.4 and
23.9L per session, given the heterogeneous cut-offs in trials that have suggested a difference
in mortality. A large, well-designed, multi-centre, multi-national randomised controlled trial
examining this issue is indicated given the suggestive findings of a potential benefit with high
volume HDF to date.
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